Biotech 2050 Podcast
By Biotech 2050
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by Biotech 2050
Category: Science
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 46
Reviews: 0
Episodes: 199
Description
Biotech2050 Podcast is a think tank chronicling the disruptions changing the biotech industry over the next 50 years.
| Episode | Date |
|---|---|
|
Demystifying Drug Discovery, Ray Stevens, CEO, Structure Therapeutics
|
Apr 03, 2024 |
|
Navigating The Evolving Landscape of Inflammation Research, Scott Megaffin, CEO, Adiso Therapeutics
|
Mar 27, 2024 |
|
Biotech's Game Changers & Revolutionizing Therapeutics, Dr. Mammen, CEO, FogPharma
|
Mar 20, 2024 |
|
The Race to Cure Untreatable Cancers, Ken Galbraith, Chair and CEO, Zymeworks
|
Mar 13, 2024 |
|
Innovation in Precision Therapies for CNS Diseases, Craig Chambliss, Co-Founder and CEO, Neurelis
|
Mar 06, 2024 |
|
Unlocking Genetic Medicine's Full Potential, Tuyen Ong, CEO, Ring Therapeutics
|
Feb 28, 2024 |
|
Aging Biology and The Power of Human Data, Kristen Fortney, Co-Founder and CEO, BioAge
|
Feb 21, 2024 |
|
The Intersection Of Tech and Biotech, Chris Gibson, Co-Founder & CEO, Recursion
|
Feb 14, 2024 |
|
Psychedelics, Longevity, and Wellbeing, Christian Angermayer, Founder, Apeiron Investment Group
|
Feb 07, 2024 |
|
Navigating Platform vs Product Tension, David Kirn, Co-Founder & CEO, 4DMT
|
Jan 31, 2024 |
|
Adapting Through Disruption in Biotech, David Esposito, President & CEO, ONL Therapeutics
|
Jan 10, 2024 |
|
Overcoming Capital Challenges in Biotech, Jak Knowles, President & CEO, Affini-T Therapeutics
|
Dec 13, 2023 |
|
A novel approach to advancing breast cancer therapy, Sean Bohen, President & CEO, Olema Oncology
|
Dec 06, 2023 |
|
The promise of precision oncology, Troy Wilson, President & CEO, Kura Oncology
|
Nov 29, 2023 |
|
Next-gen gene editing, Keith Gottesdiener, President & CEO, Jeremy Duffield, CSO, Prime Medicine
|
Nov 22, 2023 |
|
Developing medicines for broad populations of cancer patients, Brett Hall, CSO, Immuneering
|
Nov 15, 2023 |
|
Harnessing the power of microglia, Ivana Magovčević-Liebisch, President & CEO, Vigil Neuroscience
|
Nov 08, 2023 |
|
Revolutionizing eyecare treatment, Bobak Azamian, CEO & Chairman, Tarsus Pharmaceuticals
|
Nov 01, 2023 |
|
Targeting validated drivers of cancer, Nima Farzan, CEO, Kinnate Biopharma
|
Oct 25, 2023 |
|
Advancing bold therapies for neuronal health, Mark Litton, President & CEO, Athira Pharma
|
Oct 18, 2023 |
|
Pioneering RNA editing to deliver the future of medicine, Ram Aiyar, President & CEO, Korro Bio
|
Oct 11, 2023 |
|
Unlocking the technological potential of biology, Seemay Chou, Co-Founder & CEO, Arcadia Science
|
Oct 04, 2023 |
|
Pioneering tRNA therapeutics, Michelle Werner, CEO, Alltrna & CEO-Partner, Flagship Pioneering
|
Sep 27, 2023 |
|
Breaking new ground in the treatment of fibrosis, Bernard Coulie, President & CEO, Pliant Tx
|
Sep 20, 2023 |
|
Transforming medicine through precision epigenomic control, Mahesh Karande, Pres. & CEO, Omega Tx
|
Sep 13, 2023 |
|
Catalyzing the next generation of mRNA medicines, Joseph Payne, Founder, Pres. & CEO, Arcturus Tx
|
Sep 06, 2023 |
|
Advancing muscle biology, Robert Blum, Pres. & CEO, & Fady Malik, EVP, Research & Dev., Cytokinetics
|
Aug 30, 2023 |
|
Transforming the treatment of neuromuscular diseases, James McArthur, CEO, PepGen
|
Aug 23, 2023 |
|
Conquering new frontiers in cell therapy, Paul Lammers, CEO, Triumvira Immunologics
|
Aug 16, 2023 |
|
Next-gen immunotherapies for cancer, Andrew Scharenberg, Co-founder & CEO, Umoja Biopharma
|
Aug 09, 2023 |
|
Transforming medicine through non-viral gene therapy, Theresa Heah, CEO, Intergalactic Tx
|
Aug 02, 2023 |
|
Transforming diseased cells into coordinators of cure, Volker Herrmann, President & CEO, Sonata Tx
|
Jul 26, 2023 |
|
Breaking barriers in rare genetic mitochondrial diseases, Greg Flesher, Pres. & CEO, Reneo
|
Jul 19, 2023 |
|
Correcting abnormal gene expression in oncology, Adrian Gottschalk, Pres. & CEO, Foghorn Tx
|
Jul 12, 2023 |
|
Epigenetic therapies for organ injury & chronic liver diseases, Jim Brown, Pres. & CEO, DURECT
|
Jul 05, 2023 |
|
New vision for preventing & curing age-related diseases, James Peyer, Founder & CEO, Cambrian Bio
|
Jun 28, 2023 |
|
Revolutionizing T-cells for solid tumor cell therapies, Gary Lee, CSO, Lyell Immunopharma
|
Jun 21, 2023 |
|
Mobilizing the immune system to combat disease, Liang Schweizer, Founder & CEO, HiFiBiO Tx
|
Jun 14, 2023 |
|
BIO Special: New vision for immunotherapy, Detlev Biniszkiewicz, Founder & CEO, NextPoint Tx
|
Jun 07, 2023 |
|
BIO Special: Advancing kidney disease care, Eric Dobmeier, President & CEO, Chinook Tx
|
Jun 06, 2023 |
|
BIO Special: Advancing heart disease treatment, Faraz Ali, CEO, Tenaya Therapeutics
|
Jun 05, 2023 |
|
Drugging the undruggable with Gregory Verdine, Co-Founder, President & CEO, Lifemine Tx & FogPharma
|
May 31, 2023 |
|
Pioneering precision therapies for cancer & blood disorders, Kate Haviland, CEO, Blueprint Medicines
|
May 30, 2023 |
|
Targeting highly dynamic proteins to develop precision medicines, Asit Parikh, Pres. & CEO, MOMA Tx
|
May 24, 2023 |
|
RNA-guided programmable therapeutics for fibrosis, Samir Ounzain, CEO & Co-Founder, HAYA Tx
|
May 17, 2023 |
|
Single-course gene editing for cardiovascular disease, Sekar Kathiresan, Co-Founder & CEO, Verve Tx
|
May 10, 2023 |
|
Leading personalized immune medicines, Harlan Robins, CSO & Co-Founder, Adaptive Biotechnologies
|
May 03, 2023 |
|
Advancing RNA medicines in genetic diseases, Paul Bolno, President & CEO, Wave Life Sciences
|
Apr 26, 2023 |
|
Leadership in revolutionizing cancer immunotherapy, Garo Armen, Ph.D., Chairman & CEO, Agenus
|
Apr 19, 2023 |
|
Revolutionizing brain health: CNS innovations, AI & more, Craig Thompson, CEO, Cerevance
|
Apr 12, 2023 |
|
Mental health: psychedelics & beyond, Florian Brand, CEO, & Srinivas Rao, CSO, atai Life Sciences
|
Apr 05, 2023 |
|
High-impact oral small molecule therapy in autoimmune disease, Kevin Judice,Co-Founder & CEO,DICE Tx
|
Mar 29, 2023 |
|
A new vision in inflammatory disease: RNAseq led precision medicine, Tariq Kassum, CEO, Celsius Tx
|
Mar 22, 2023 |
|
Pioneering therapeutics targeting cellular stress pathways, Prakash Raman, President & CEO, Ribon Tx
|
Mar 15, 2023 |
|
Novel viral vectors in gene therapy, Joel Schneider, CEO & Robert Kotin, Founder, Carbon Biosciences
|
Mar 08, 2023 |
|
Advancing medicines that matter, Matt Gline, CEO, Roivant Sciences
|
Mar 01, 2023 |
|
Transforming chemotherapy for better patient outcomes, Jack Bailey, CEO, G1 Therapeutics
|
Feb 22, 2023 |
|
Personalized regenerative medicines, Nabiha Saklayen, PhD, Co-Founder & CEO, Cellino
|
Feb 15, 2023 |
|
Engaging the immune system against disease, Andrew Allen, Co-Founder, President & CEO, Gritstone bio
|
Feb 08, 2023 |
|
Novel approach to targeted protein degradation, Nicki Thompson, CEO, Amphista Therapeutics
|
Feb 01, 2023 |
|
Envisioning people focused clinical trials, Michael Rosenblatt, VP of Clinical Operations, Roche
|
Jan 25, 2023 |
|
Power of RNA to restore healthy gene expression, Josh Mandel-Brehm, President & CEO, CAMP4 Tx
|
Jan 18, 2023 |
|
JPM23 Special: Rare diseases, Eslie Dennis, Kyowa Kirin, Arthur Suckow, DTx, & James Mackay, Aristea
|
Jan 11, 2023 |
|
JPM23 Special: Redefining cystic fibrosis treatment, Mike Cloonan, Pres. & CEO, Sionna Tx
|
Jan 10, 2023 |
|
JPM23 Special: Advancing RNA Therapeutics, Geoff Nosrati, CBO, Nutcracker Therapeutics
|
Jan 09, 2023 |
|
133. Pharma & Profits, John LaMattina, former Pres. of R&D, Pfizer, Senior Partner, PureTech Health
|
Jan 04, 2023 |
|
132. Targeting ferroptosis cell death for cancer and beyond, Luba Greenwood, CEO, Kojin Therapeutics
|
Dec 21, 2022 |
|
131. Epigenetic approaches to rare diseases, Amber Salzman, CEO, Epic Bio
|
Dec 14, 2022 |
|
130. Breast cancer: targeted treatment options, Sean Bohen, President & CEO, Olema Oncology
|
Dec 07, 2022 |
|
129. Progress in complex diseases: NASH, Long COVID, and beyond, Bill Hinshaw, Pres. & CEO, Axcella
|
Nov 30, 2022 |
|
128. Treating rare neurological diseases & guiding mission, Jeremy Levin, Chairman & CEO, Ovid Tx
|
Nov 23, 2022 |
|
127. Immuno-oncology landscape, Keith Flaherty, Dir. of Clin. Research, Mass General Cancer Center
|
Nov 16, 2022 |
|
126. New frontier in biology: harnessing the power of the repeatome, Dennis Zaller, CSO, ROME tx
|
Nov 09, 2022 |
|
125. Gene circuits for smarter medicine, Tim Lu, Co-Founder & CEO, & Kanya Rajangam, CMDO, Senti Bio
|
Nov 02, 2022 |
|
124. Leukemia and beyond: Next-gen precision cell therapy, Ivan Dimov, Co-Founder & CEO, Orca Bio
|
Oct 26, 2022 |
|
123. Nano-rare patients & rare diseases, Stanley Crooke, Founder & CEO, n-Lorem Foundation
|
Oct 19, 2022 |
|
122. New vision for cell & gene therapy, Andrew Sandford & Michael Paglia, ElevateBio BaseCamp
|
Oct 12, 2022 |
|
121. Mission-driven biotech investing, Josh Wolfe, Co-founder & Managing Partner, Lux Capital
|
Oct 05, 2022 |
|
120. Beyond CD8 immuno-oncology, Amanda Wagner, President and CEO, Immunitas Therapeutics
|
Sep 28, 2022 |
|
119. Special Edition: Quiet Leader, Loud Results, Ankit Mahadevia, Author
|
Sep 21, 2022 |
|
118. One team, one mission: tackling pruritus, Chris Posner, President & CEO, Cara Therapeutics
|
Sep 14, 2022 |
|
117. Pioneering cell biology drug discovery, Rachel Meyers, CSO, Faze Medicines
|
Aug 31, 2022 |
|
116. Retinal restoration and visions for growth, Brian Culley, CEO, Lineage Cell Therapeutics
|
Aug 24, 2022 |
|
115. Innovations in diabetes therapies, Timothy Kieffer, CSO, Manasi Sinha Jaiman, CMO, ViaCyte
|
Aug 17, 2022 |
|
114. Advancing cell therapy and multiple myeloma treatment, Ying Huang, CEO, Legend Biotech
|
Aug 10, 2022 |
|
113. Envisioning VDC cancer treatment, Elisabet de los Pinos, CEO, Aura Biosciences
|
Aug 03, 2022 |
|
112. New approaches in CNS diseases, Brad Margus, Co-founder and Executive Chairman, Cerevance
|
Jul 27, 2022 |
|
111. Synthetic biology & probiotics, Aoife Brennan, President & CEO, Synlogic
|
Jul 20, 2022 |
|
110. Novel cell and gene therapies, Mark Gergen, CEO, Poseida Therapeutics, Inc.
|
Jul 13, 2022 |
|
109. Gene therapy CDMO, Tim Miller, CEO, Erandi De Silva, SVP of Prod. Dev., Forge Biologics
|
Jun 29, 2022 |
|
108. Vibe Bio launches to transform drug development, Alok Tayi Ph.D. and Susanna Harris Ph.D.
|
Jun 22, 2022 |
|
107. Fighting infectious diseases with biologics, Paul Garofolo, Co-founder & CEO, Locus Biosciences
|
Jun 15, 2022 |
|
106. Next-Gen CRISPR applications, Trevor Martin, Co-founder & CEO, Mammoth Biosciences
|
Jun 08, 2022 |
|
105. Gene therapy in hearing loss, Laurence Reid, PhD, CEO, Decibel Therapeutics
|
Jun 01, 2022 |
|
104. Embracing nerve repair, Karen Zaderej, CEO, Chairman, and President, Axogen
|
May 25, 2022 |
|
103. Patient-driven thrombosis innovations, John Glasspool, CEO, Anthos Therapeutics
|
May 18, 2022 |
|
102. Vanquishing Parkinson's Disease, Jim Sullivan, PhD, Co-founder & CEO, Vanqua Bio
|
May 11, 2022 |
|
101. Revolutionizing genetic medicine, Paula Soteropoulos, Chairman of the Board, Ensoma
|
May 04, 2022 |
|
100. Disruptive forces in biotech, Jake Becraft, Lex Rovner, Josh Mandel-Brehm, & Nabiha Saklayen
|
Apr 27, 2022 |
|
99. Precision medicine for sepsis, Tim Sweeney, Co-Founder and CEO, Inflammatix, Inc.
|
Apr 20, 2022 |
|
98. Brain health disorders, Al Robichaud, Ph.D., CSO, Sage Therapeutics
|
Apr 13, 2022 |
|
97. Patient driven treatments in rare diseases, Stuart Peltz, Founder & CEO, PTC Therapeutics
|
Apr 06, 2022 |
|
96. Obesity & rare disease, Patrick Kleyn, SVP and Head of Translational R&D,Rhythm Pharmaceuticals
|
Mar 30, 2022 |
|
95. Gene writing, Dr. Jake Rubens, Co-Founder & CIO, Hari Pujar, COO, Tessera Therapeutics
|
Mar 23, 2022 |
|
94. Cell therapy in a war on cancer, Kleanthis Xanthopoulos, Co-Founder & CEO, Shoreline Biosciences
|
Mar 16, 2022 |
|
93. Human-centric data and AI for improved drug development, David Berry, Founder & CEO, Valo Health
|
Mar 09, 2022 |
|
92. Software driven biology for small molecule mRNA drugs, Yochi Slonim, Co-founder & CEO, Anima
|
Mar 02, 2022 |
|
91. tRNA therapies, Lovisa Afzelius, Founding CEO, Theonie Anastassiadis, Co-founder & CIO, Alltrna
|
Feb 23, 2022 |
|
90. From pharma to founding a biotech, James Mackay, Founder, President & CEO, Aristea Therapeutics
|
Feb 16, 2022 |
|
89. Regenerative medicine pioneer, Laura Niklason, Founder, President, & CEO, Humacyte, Inc.
|
Feb 09, 2022 |
|
88. Biologics in autoimmune and kidney disease, Marshall Fordyce, CEO and Founder, Vera Therapeutics
|
Feb 02, 2022 |
|
87. Patient-centric Duchenne gene therapy, Joel Schneider, COO, Solid Biosciences
|
Jan 26, 2022 |
|
86. Resilient to the core, Trish Hurter, CEO, Jess Ballinger, President & COO, Lyndra Therapeutics
|
Jan 19, 2022 |
|
85. Genomic testing for precision oncology, Shawn Leland, Founder and CEO, Elevation Oncology
|
Jan 12, 2022 |
|
84. Leadership insights, Paul Biondi, President, Pioneering Medicines,Flagship Pioneering initiative
|
Jan 05, 2022 |
|
83. Season 2 Wrap Up, Rahul Chaturvedi and Alok Tayi
|
Dec 15, 2021 |
|
82. RNA therapeutics for neurological indications, Barry Ticho, CMO, Stoke Therapeutics
|
Dec 08, 2021 |
|
81. Innovations for narcolepsy, Greg Divis, CEO, Avadel Pharmaceuticals
|
Dec 01, 2021 |
|
80. Targeted cancer immunotherapies, Chip Clark, President and CEO, Genocea
|
Nov 17, 2021 |
|
79. Leadership in rare diseases, Srini Ramanathan, SVP, R&D Sciences, Horizon Therapeutics
|
Nov 10, 2021 |
|
78. Translating lab insights for outcomes to cancer patients, Heike Keilhack, CSO,Ribon Therapeutics
|
Nov 03, 2021 |
|
77. Battling rare diseases: patients and scientists, Ethan Perlstein, Founder and CEO, Perlara
|
Oct 27, 2021 |
|
76. Advancing immuno-oncology, Michel Detheux, President and CEO, iTeos Therapeutics
|
Oct 20, 2021 |
|
75. Innovations in cell therapies via microfluidics, Armon Sharei, CEO and Founder, SQZ Biotech
|
Oct 13, 2021 |
|
74. Pioneering circular oRNA therapeutics, Thomas Barnes, Chief Executive Officer, Orna Therapeutics
|
Oct 06, 2021 |
|
73. Patient focused gene editing for heart disease, Andrew Bellinger, CSO/CMO, Verve Therapeutics
|
Sep 29, 2021 |
|
72. Unlocking biologic drug production, Brian Finrow, Co-Founder and CEO, Lumen Bioscience
|
Sep 22, 2021 |
|
71. Leadership in immuno-oncology, Jeffrey Goldberg, President and CEO, Immunitas Therapeutics
|
Sep 15, 2021 |
|
70. Modern treatments for psoriasis and atopic dermatitis, Todd Zavodnick, CEO, Dermavant Sciences
|
Aug 25, 2021 |
|
69. Antibodies in immuno-oncology, Alison O'Neill, Chief Medical Officer, Surface Oncology
|
Aug 18, 2021 |
|
68. Patient-focused Wet AMD, Nancy Lurker, President & CEO, Said Saim, CTO, EyePoint Pharmaceuticals
|
Aug 11, 2021 |
|
67. ML protein therapy, Mike Nally, CEO, and Geoff von Maltzahn, Co-Founder, Generate Biomedicines
|
Aug 04, 2021 |
|
66. I’ll take “Wild Rides” for 500, Alex: Biotech Entrepreneur’s Story, Ron Cohen, CEO, Acorda
|
Jul 28, 2021 |
|
65. Patient focused precision oncology, Avanish Vellanki, Cofounder and CEO, Rain Therapeutics
|
Jul 21, 2021 |
|
64. Tech-driven acceleration in clinical trials, Benjamine Liu, Co-founder and CEO, TrialSpark
|
Jul 14, 2021 |
|
63. Building a leader in infectious diseases, Ankit Mahadevia, President and CEO, Spero Therapeutics
|
Jul 07, 2021 |
|
62. Tackling autoimmune and allergic disease, Jonathan Rigby, Group CEO, Revolo Biotherapeutics
|
Jun 23, 2021 |
|
61. Groundbreaking immunology microbe oral therapies, Simba Gill, CEO, Evelo Biosciences
|
Jun 16, 2021 |
|
60. BIOS Edition: Investing in biotech and healthcare, Yizhen Dong, Partner, Global Founders Capital
|
Jun 09, 2021 |
|
59. Targeted cancer therapies using engineered viruses, Alice Bexon, Chief Medical Officer, Vyriad
|
May 19, 2021 |
|
58. End game vaccine for COVID-19, Marty Moore, Cofounder and CEO, Meissa Vaccines
|
May 12, 2021 |
|
57. Next frontier in schizophrenia and mental health, Andrew Miller, Founder and COO, Karuna
|
May 05, 2021 |
|
56. Turning cancer on itself, Sam Mazin, Founder and CTO, Thorsten Melcher, CBO, RefleXion
|
Apr 28, 2021 |
|
55. Gene therapy for hearing loss, Heather Wolff, VP of Clinical Development Operations, Decibel
|
Apr 21, 2021 |
|
54. CRISPR treating cancer, Rachel Haurwitz, Co-founder and CEO, Caribou Biosciences
|
Apr 14, 2021 |
|
53. Leading a rare disease biopharma company, Paula Ragan, CEO and President, X4 Pharmaceuticals
|
Apr 08, 2021 |
|
52. SPACs and infectious disease past and future, Joe Hernandez, CEO, Blue Water Acquisition Corp.
|
Mar 31, 2021 |
|
51. Pioneering innovations for neurological indications, Chris Wright, CMO, Cyclerion
|
Mar 25, 2021 |
|
50. Noninvasive diagnostics for NASH and inflammatory indications, Caroline Loew, CEO, Glympse Bio
|
Mar 17, 2021 |
|
49. Restoring connections for neurodegenerative diseases, Leen Kawas, CEO, Athira Pharma
|
Mar 10, 2021 |
|
48. Anti-TNF: From Arthritis to Dementia and Fibrosis, Jim Woody, CEO, 180 Life Sciences
|
Mar 03, 2021 |
|
47. Next generation cell-free cancer and autoimmune therapeutics, Bill Newell, CEO, Sutro Biopharma
|
Feb 24, 2021 |
|
46. Fighting cancer with protein degradation, Adam Crystal, CMO, Stew Fisher, CSO, C4 Therapeutics
|
Feb 17, 2021 |
|
45. Next generation of cell therapy, Brian Culley, CEO, Lineage Cell Therapeutics
|
Feb 10, 2021 |
|
44. Revolutionizing the drug discovery marketplace, Kevin Lustig, Founder and CEO, Scientist.com
|
Feb 03, 2021 |
|
43. From health economics to COVID19 treatment, Jonathan Javitt, Co-Founder and CEO, NeuroRx Pharma
|
Jan 27, 2021 |
|
42. Combating COVID19, Mei Mei Hu, Co-Founder and CEO, and Peter Diamandis, Co-Founder, COVAXX
|
Jan 20, 2021 |
|
41. Tackling the mental health pandemic, Shawn Singh, CEO, VistaGen Therapeutics
|
Jan 13, 2021 |
|
40. Approaches to immunology, inflammation, and oncology, Dr. Luisa Salter-Cid, CSO, Gossamer Bio
|
Jan 06, 2021 |
|
39. Biotech2050 Season 1 Wrap Up: Co-Hosts, Alok Tayi and Rahul Chaturvedi
|
Dec 16, 2020 |
|
38. AI-driven early detection cancer screening from a blood test, Ken Chahine, CEO, Helio Health
|
Nov 11, 2020 |
|
37. Bringing new treatments to psychiatric orphan diseases, Ibs Mahmood, CEO, AMO Pharma
|
Nov 04, 2020 |
|
36. Harnessing the innate immune system to combat disease, RJ Tesi, CEO and CMO, INmune Bio
|
Oct 28, 2020 |
|
35. Continuous manufacturing in drug development, Matthew Bio, CEO, Snapdragon Chemistry
|
Oct 21, 2020 |
|
34. Automation and Regenerative Manufacturing, Alexander Titus, Chief Strategy Officer, ARMI
|
Oct 14, 2020 |
|
33. RNA modification gene therapy for rare disorders, Jim Burns, CEO, Kathie Bishop, CSO, Locanabio
|
Oct 07, 2020 |
|
32. Vaccine origins to combat COVID-19, Seth Lederman, Co-Founder/CEO, Tonix Pharmaceuticals
|
Sep 30, 2020 |
|
31. Drug discovery for neurodegenerative diseases, Victor Hanson-Smith, Comp. Bio., Verge Genomics
|
Sep 23, 2020 |
|
30. Genetics and synthetic biology for trailblazing drug discovery, Maria Soloveychik, CEO, SyntheX
|
Sep 16, 2020 |
|
29. Breakthrough imaging device for noninvasive cancer detection: Bob Proulx, CEO Imagion Biosystems
|
Sep 09, 2020 |
|
28. Urology medtech for BPH with insights on patient care, VC, and more Nick Damiano, CEO, Zenflow
|
Sep 02, 2020 |
|
27. Harnessing the microbiome to combat type 2 diabetes: Colleen Cutcliffe, CEO, Pendulum
|
Aug 26, 2020 |
|
26. DNA testing to proactively inform treatment: Paul Billings, CMO, Natera
|
Aug 19, 2020 |
|
25. The power of AI for precision drug discovery and development: Auransa Inc., Andy Protter, CSO
|
Aug 05, 2020 |
|
24. JoyL Silva, GM, and Nicole Strauss Pipeline Development and Innovation Lead, Pfizer CentreOne
|
Jul 29, 2020 |
|
23. Abbas Kazimi, VP of Business Development, Nimbus Therapeutics
|
Jul 22, 2020 |
|
22. Randy Schatzman, Ph.D.,CEO and Board Member, Bolt Biotherapeutics
|
Jul 15, 2020 |
|
21. Glenn Rosen, MD, Senior VP, Pre-Clinical Translational Sciences, Coherus BioSciences
|
Jul 09, 2020 |
|
20. Diego Ardigò, MD, PhD, Head of Research and Development, Global Rare Diseases, Chiesi Group
|
Jul 01, 2020 |
|
19. Mike Clayman, MD, CEO and Co-Founder, Flexion Therapeutics
|
Jun 24, 2020 |
|
18. Grace Colón, PhD, President and CEO, InCarda Therapeutics
|
Jun 17, 2020 |
|
17. Sachin Chandran, PhD, Exec. Dir., Head of Pharmaceutical Sciences, Catabasis Pharmaceuticals
|
Jun 10, 2020 |
|
16. Mike Novotny, Founder and CEO, Medrio
|
Jun 03, 2020 |
|
15. David Mace, Co-Founder and CEO, SwiftScale Biologics
|
May 27, 2020 |
|
14. David Bates, PhD, Co-Founder, Linus Health
|
May 20, 2020 |
|
13. Stephan Kontos, PhD, Co-Founder and CSO, Anokion
|
May 13, 2020 |
|
12. Robert Gould, PhD, President & CEO, and Owen Wallace, PhD, CSO, Fulcrum Therapeutics
|
May 04, 2020 |
|
11. Controllable cell and gene therapies, Paul Wotton, PhD, CEO, Obsidian Therapeutics
|
Apr 27, 2020 |
|
10. Chris Murray, Sr. VP, Technical Operations, Blueprint Medicines
|
Feb 26, 2020 |
|
9. The next frontier in cancer treatment: Foghorn Therapeutics and Chromatin Dysregulation
|
Jan 23, 2020 |
|
8. Dr. Florian Wegener, Co-Founder and CEO of ZAGENO
|
Jan 07, 2020 |
|
7. Raman Sehgal, Founder and Global President of Ramarketing
|
Dec 17, 2019 |
|
6. Kevin J. Bittorf, PhD: Consultant and Founder, Simulation LLC
|
Dec 10, 2019 |
|
5. Jon Hennek: Systems Innovation Team Co-Lead at Indigo Ag
|
Dec 03, 2019 |
|
4. Sven Karlsson: Co-founder, COO and CBO of Platelet BioGenesis
|
Nov 05, 2019 |
|
3. Dr. Jo Viney: Co-Founder, President and CSO of Pandion Therapeutics
|
Oct 29, 2019 |
|
2. John Keilty: Chief Data Sciences Officer at Decibel Therapeutics
|
Oct 23, 2019 |
|
1. Lee Cooper: Patient advocate and Founder of Enlight Bio
|
Oct 15, 2019 |
|
Welcome to the Biotech2050 Podcast
|
Oct 01, 2019 |